Latanoprost acid

SKU: orb1707093

Description

Latanoprost acid is a selective prostanoid receptor agonist that suppresses RANKL-induced osteoclast formation and activity by inhibiting the c-fos/NFATc1 pathway. It is a research tool for studying intraocular pressure reduction and bone metabolism, with applications in both in vitro osteoclastogenesis assays and in vivo models of glaucoma.

Research Area

Immunology & Inflammation, Metabolism Research, Pharmacology & Drug Discovery

Key Properties

• CAS Number: 41639-83-2
• MW: 390.51
• Purity: 97.96%
• Formula: C₂₃H₃₄O₅
• SMILES: O[C@H](CC[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(O)=O)CCc1ccccc1
• Target: Prostaglandin Receptor,GPCR
• Solubility: DMSO:27.5 mg/mL (70.42 mM);10% DMSO+40% PEG300+5% Tween 80+45% Saline:2 mg/mL (5.12 mM)

Bioactivity

• In Vivo:
  Latanoprost acid (i.p.; 20 mg/kg; once daily for 7 days) effectively prevents LPS-induced bone destruction.
• In Vitro:
  Latanoprost acid (10, 20 μM) reduce the protein expressions of c-fos and NFATc1 thus inhibitin the mature osteoclast formation in BMMs. Latanoprost acid (1 μM) and RANKL(5 ng/mL) significantly inhibit ERK, p38, AKT and JN.

Storage & Handling

• Storage: store at low temperature | Pure form: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

Latanoprost acid, FP, prostanoid selective FP receptor

Compound Identifiers

PubChem CID

6441636